Co-founder and CEO Dr Muhunthan Thillai came up with Qureight after he couldn’t confidently read a patient’s CT scan. The funds will cover a new AI imaging lab and expand into asthma, pulmonary hypertension, and bronchiectasis. From a CT Scan To An AI CompanyWithout an engineering background, Dr Muhunthan Thillai co-founded Qureight in 2018 with Dr Alessandro Ruggiero. AI Lung models the airways and blood vessels, showing exactly how a drug affects disease progression. The lung and heart clinical trials market is projected to hit $27.5 billion by 2030, growing 6.9% a year.